Policy

Compass Pathways Faces FDA Approval and DEA Scheduling Hurdles in US

As Compass Pathways nears a pivotal FDA decision on its psilocybin therapy, attention shifts to the DEA's role in rescheduling, which will determine real-world access for patients and providers.

Published November 20, 2026 Read 3 min 720 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Compass Pathways Nears FDA Decision for Psilocybin Therapy

Compass Pathways, a leading developer of psychedelic-assisted therapies, is approaching a crucial decision point with the US Food and Drug Administration (FDA) for its investigational psilocybin treatment for treatment-resistant depression. The company's lead candidate, COMP360, has completed Phase 3 clinical trials, with topline results expected to inform the FDA's decision-making process in late 2026 or early 2027. If approved, COMP360 would become the first psilocybin-based therapy to gain FDA approval for a psychiatric indication, marking a significant milestone for both the company and the broader psychedelic medicine field.

The FDA's review process, governed by the agency's Center for Drug Evaluation and Research (CDER), evaluates safety, efficacy, and manufacturing standards under a New Drug Application (NDA). Compass Pathways submitted its NDA in Q3 2026, following positive Phase 2b results published in the New England Journal of Medicine and registration on ClinicalTrials.gov (NCT03775200). The FDA's decision will hinge on clinical endpoints, adverse event profiles, and risk mitigation strategies such as Risk Evaluation and Mitigation Strategies (REMS).

DEA Scheduling: The Next Regulatory Barrier

FDA approval alone does not guarantee immediate patient access to psilocybin therapy in the United States. The Drug Enforcement Administration (DEA) controls the scheduling of substances under the Controlled Substances Act (CSA), and psilocybin is currently classified as a Schedule I substance—defined as having no accepted medical use and a high potential for abuse. For COMP360 to be legally prescribed, the DEA must reschedule or otherwise permit medical use of psilocybin following FDA approval.

The DEA has up to 90 days after FDA approval to initiate rescheduling proceedings, but the process can be protracted and is not automatic. Stakeholders should note that the agency may require additional scientific and medical evaluation, including public comment periods and input from the Department of Health and Human Services (HHS). A recent precedent is the DEA's handling of Epidiolex (cannabidiol), which was rescheduled from Schedule I to Schedule V within three months of FDA approval in 2018. However, unlike cannabidiol, psilocybin's psychedelic effects and public perception may prompt more extensive review and debate.

Policy and Research Implications for Psychedelic Medicines

The dual regulatory pathway—requiring both FDA approval and DEA rescheduling—creates a unique bottleneck for psychedelic therapies in the US. This two-step process means that even robust clinical evidence and FDA endorsement do not directly translate into clinical availability. For researchers, this underscores the importance of designing trials and data packages that address not only efficacy and safety, but also diversion risk, abuse potential, and public health considerations that the DEA will scrutinize.

Policymakers and industry advocates are increasingly aware of this regulatory gap. Some have called for legislative solutions, such as the Breakthrough Therapies Act (S. 2934, 2025), which would require the DEA to reschedule substances designated as breakthrough therapies by the FDA. However, as of November 2026, no such legislation has passed, and the regulatory status quo remains.

Risks, Unknowns, and Real-World Access Challenges

Significant risks and uncertainties remain for Compass Pathways and other psychedelic medicine developers. The FDA could impose restrictive REMS or require post-marketing surveillance, adding complexity to clinical implementation. The DEA could delay or deny rescheduling, leaving patients and providers in legal limbo. State laws may also diverge from federal policy, creating a patchwork of access and enforcement risks.

An often-overlooked risk is the potential for discordant timelines between FDA and DEA actions, which could stall commercial rollout and frustrate patients seeking new options for treatment-resistant depression. Additionally, the DEA may impose special handling, storage, and prescribing requirements even if rescheduling occurs. These operational burdens could limit the number of clinics able or willing to offer psilocybin therapy, regardless of federal approval.

Outlook: Navigating the Dual Agency Landscape

Compass Pathways' progress toward FDA approval represents a watershed moment for psychedelic medicine, but the path to real-world impact depends on coordinated action by both the FDA and DEA. Stakeholders should prepare for a multi-stage regulatory process, anticipate operational challenges, and engage with both agencies to facilitate safe, equitable access. The outcome of this case will set a precedent for future psychedelic therapies and may inform broader drug policy reform efforts in the US.

How we research: This analysis was prepared by Dr. Alex Morgan, PhD (Neuropharmacology), reviewed by Dr. Emily Chen, JD, on 2026-11-21. Primary sources include FDA, DEA, and ClinicalTrials.gov records.

Primary source: https://news.google.com/rss/articles/CBMiW0FVX3lxTE1qYm1jUUVmblZvRzRvZmczN2JVSHptMUF1M1FtWjFiNFhiZ2xhb1g5MjBFRkFPSXFSOU5LMjU4ekVGMkRISU41M29LWDRXYkxURGU1YWlxbzM5WEk?oc=5 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.